Amedeo Smart

Free Medical Literature Service

 

Amedeo

Migraine
  Free Subscription

Articles published in
Cephalalgia
    November 2025
  1. TFELT-HANSEN P, Hougaard A
    Some observed problems of the evidence presented for zolmitriptan nasal spray in the "Evidence-Based Recommendations of Pharmacological Treatment of Migraine Attacks".
    Cephalalgia. 2025;45:3331024251393937.
    >> Share

  2. ORNELLO R, Russo A, Orologio I, Silvestro M, et al
    Response to the Letter by Tfelt-Hansen and Hougaard "Some observed problems of the evidence presented for zolmitriptan nasal spray in the "Evidence-Based Recommendations of Pharmacological Treatment of Migraine Attacks".
    Cephalalgia. 2025;45:3331024251393936.
    >> Share

  3. LOOSE L, Paemeleire K, Goadsby PJ, MaassenVanDenBrink A, et al
    What's a migraine day? Analysis of the variety in the definition of a migraine day across phase III trials with drugs targeting the CGRP pathway.
    Cephalalgia. 2025;45:3331024251393986.
    >> Share

  4. ZORRILLA E, Duong TL, Pina CL, Russo AF, et al
    Cannabinoids rescue migraine symptoms caused by central CGRP administration in mice.
    Cephalalgia. 2025;45:3331024251392103.
    >> Share

  5. DUMKRIEGER G
    The promise of machine learning in predicting migraine attacks.
    Cephalalgia. 2025;45:3331024251391207.
    >> Share

  6. LIN C, Li Y, Wang Z, Duan C, et al
    Abnormal neurovascular coupling in the precuneus associated with migraine chronification: A multimodal magnetic resonance imaging study.
    Cephalalgia. 2025;45:3331024251396031.
    >> Share

  7. PARDO K, Schwedt TJ, Cutrer FM, Chiang CC, et al
    The promise of artificial intelligence and machine learning for migraine treatment outcome prediction: A narrative review.
    Cephalalgia. 2025;45:3331024251395541.
    >> Share

  8. ORNELLO R, Maassen van den Brink A, Puledda F, Sandoe CH, et al
    Migraine management during pregnancy, breastfeeding and in women planning pregnancy.
    Cephalalgia. 2025;45:3331024251393945.
    >> Share

  9. POZO-ROSICH P, Lopez JAG, Lisewski P, Aslan AN, et al
    A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.
    Cephalalgia. 2025;45:3331024251391378.
    >> Share

  10. ASHINA M, McAllister P, Gaul C, Leyva-Rendon A, et al
    Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.
    Cephalalgia. 2025;45:3331024251395298.
    >> Share

  11. TANG Y, Li H, Dong B, Sha L, et al
    Divergent functional connectivity patterns in menstrually-related and non-menstrual migraine: A large-scale resting-state fMRI study.
    Cephalalgia. 2025;45:3331024251396102.
    >> Share

  12. PISTOLESI A, De Cesaris F, Buonvicino D, Chiarugi A, et al
    Biodistribution of atogepant and rimegepant in mouse peripheral and central structures of relevance to migraine pathogenesis.
    Cephalalgia. 2025;45:3331024251378713.
    >> Share

    October 2025
  13. PERES MFP, Yuan H, Tassorelli C
    Complementary, but not equivalent: Clarifying the role of RWE and RCT in migraine research.
    Cephalalgia. 2025;45:3331024251381333.
    >> Share

  14. PERES MFP, Yuan H, Tassorelli C
    The importance of treating migraine attacks early - even in youth: A real-world argument for neuromodulation.
    Cephalalgia. 2025;45:3331024251370675.
    >> Share

  15. LAX DN, Stark-Inbar A, Ironi A, Tomaschek I, et al
    It's not either-or: Why migraine care needs both real-world evidence studies and randomized controlled trials.
    Cephalalgia. 2025;45:3331024251381337.
    >> Share

  16. ZHANG M, Guo A, Wu J, Wang H, et al
    Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China.
    Cephalalgia. 2025;45:3331024251371686.
    >> Share

  17. TAMAYO DE LEON CD, Gama-Reyes EG, Paredes Moreno FA, Galnares-Olalde JA, et al
    Adjunctive occipital nerve block for emergency treatment of acute migraine: A randomized, controlled trial.
    Cephalalgia. 2025;45:3331024251381764.
    >> Share

  18. YU S, Matsumori Y, Kim BK, Gryglas-Dworak A, et al
    Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.
    Cephalalgia. 2025;45:3331024251386095.
    >> Share

  19. POZO-ROSICH P, Blumenfeld AM, Lipton RB, DeGryse RE, et al
    OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial.
    Cephalalgia. 2025;45:3331024251370769.
    >> Share

  20. DA LUZ FMR, Kaup AO, Baggio DF, Costa FHR, et al
    Efficacy of different cannabinoid compounds on migraine-like responses in female rats.
    Cephalalgia. 2025;45:3331024251386794.
    >> Share

  21. MCCAIN CR, Parrish MH, Melikov P, Rosamond WD, et al
    Introducing a risk score for predicting ischemic stroke in migraine with or without visual aura.
    Cephalalgia. 2025;45:3331024251388094.
    >> Share

  22. YUAN H, Orr SL, Al-Karagholi MAM, Ashina M, et al
    International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine.
    Cephalalgia. 2025;45:3331024251388377.
    >> Share

  23. GARCIA LB, Ferreira AJ, Hussein MA, Kowacs PA, et al
    What does ChatGPT know about Migraine? A comparative-descriptive analysis.
    Cephalalgia. 2025;45:3331024251387684.
    >> Share

  24. SILVA NVD, Bevilaqua-Grossi D, Pradela J, Dach F, et al
    Cervical musculoskeletal dysfunctions in pediatric migraine: A cross-sectional study.
    Cephalalgia. 2025;45:3331024251387033.
    >> Share

  25. FOFI L, Altamura C, Marcosano M, Brunelli N, et al
    The clinical outcome of patients starting monoclonal antibodies anti-CGRP with concomitant migraine preventive treatments.
    Cephalalgia. 2025;45:3331024251378776.
    >> Share

  26. MATHARU MS, Silberstein S, Yuan H, Edgar D, et al
    Migraine-related disability according to headache frequency subclassifications: A systematic review and meta-analysis.
    Cephalalgia. 2025;45:3331024251385965.
    >> Share

  27. MASCARELLA D, Zhuang ZA, Gliga O, Santis F, et al
    Migraine in monogenic disorders: Shedding light on new therapeutic targets.
    Cephalalgia. 2025;45:3331024251389241.
    >> Share

  28. OLIVEIRA AB, Barbosa F Jr, Santos IS, Peres MFP, et al
    Selenium levels as a sex-specific predictor of migraine in the ELSA-Brasil study.
    Cephalalgia. 2025;45:3331024251386768.
    >> Share

  29. BOTROS J, Metzler AI, Darrow DP, Peterson CM, et al
    Toward ICHD-4: Aligning ICHD and ICOP criteria for trigeminal autonomic cephalalgias and migraine.
    Cephalalgia. 2025;45:3331024251391751.
    >> Share

  30. POZO-ROSICH P, Caronna E, Sacco S, Peres MFP, et al
    Early treatment in migraine - A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society.
    Cephalalgia. 2025;45:3331024251387721.
    >> Share

  31. REES TA, Doukhi D, Wang VS, Balcerbula A, et al
    Neck pain in migraine: A narrative review and steps to correct evaluation and treatment.
    Cephalalgia. 2025;45:3331024251387449.
    >> Share

  32. AILANI J, Tomaschek I, Stark-Inbar A, Shmuely S, et al
    The effect of treatment onset time on acute efficacy in migraine patients treating with remote electrical neuromodulation (REN).
    Cephalalgia. 2025;45:3331024251370696.
    >> Share

    September 2025
  33. GOADSBY PJ, Ruiz de la Torre E, Maassen van den Brink A, Irimia P, et al
    Migraine stigma and general knowledge of migraine: A cross-sectional European survey.
    Cephalalgia. 2025;45:3331024251368251.
    >> Share

  34. IFERGANE G
    Reinterpreting migraine in a societal evolutionary context.
    Cephalalgia. 2025;45:3331024251374315.
    >> Share

  35. MOSKOWITZ MA
    Rethinking migraine with aura: Why cortical spreading depolarization (depression), not aura, causes headaches.
    Cephalalgia. 2025;45:3331024251370629.
    >> Share

  36. VIANA M, Peres MFP
    The spectrum of migraine aura: Towards a precise phenotypic classification.
    Cephalalgia. 2025;45:3331024251372621.
    >> Share

  37. CASILLO F, Sebastianelli G, Abagnale C, Di Renzo A, et al
    Brain imaging in migraine with and without aura: Similarities and differences.
    Cephalalgia. 2025;45:3331024251365807.
    >> Share

  38. ROMERO-REYES M, Akerman S, Rapoport AM
    Optimising combined treatment for migraine and temporomandibular disorders (TMDs).
    Cephalalgia. 2025;45:3331024251368882.
    >> Share

  39. FERNANDES C, Gil-Gouveia R
    Deciphering the mechanisms: Pathophysiology of migraine-related cognitive dysfunction.
    Cephalalgia. 2025;45:3331024251368328.
    >> Share

  40. PIETRA AD, Kuburas A, Russo AF
    PACAP versus CGRP in migraine: From mouse models to clinical translation.
    Cephalalgia. 2025;45:3331024251364242.
    >> Share

  41. CLEMENTE L, Paparella G, Scannicchio S, Abbatantuono C, et al
    Dorso lateral prefrontal cortex stimulation with TMS in chronic migraine individuals refractory to anti-CGRP monoclonal antibodies: Clinical, neuropsychological and neurophysiological effects.
    Cephalalgia. 2025;45:3331024251364843.
    >> Share

  42. ROBBLEE J, Khan FA, Marmura MJ, O'Brien HL, et al
    Reaching international consensus on the definition of refractory migraine using the Delphi method.
    Cephalalgia. 2025;45:3331024251367767.
    >> Share

  43. BRACA S, Santoro V, Sebastianelli G, Schankin CJ, et al
    Visual snow vs. migraine aura: Debate summary and novel insights into the syndrome.
    Cephalalgia. 2025;45:3331024251365908.
    >> Share

  44. SCHAIN AJ, Delgado Fajardo D, Strassman AM, Kulkarni S, et al
    OnabotulinumtoxinA alters pro- and anti-inflammatory dural macrophage response to CSD in female mice.
    Cephalalgia. 2025;45:3331024251378730.
    >> Share

  45. MATSUMORI Y, Yamada H, Nagaseki Y, Shimizu K, et al
    Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE).
    Cephalalgia. 2025;45:3331024251374569.
    >> Share

    August 2025
  46. ALPAY B, Christensen RH, Al-Khazali HM, Ashina M, et al
    Substance P and the trigeminovascular system: From preclinical mechanisms to human headache induction.
    Cephalalgia. 2025;45:3331024251355944.
    >> Share

  47. VAGHI G, Corrado M, Pocora MM, Bighiani F, et al
    Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis.
    Cephalalgia. 2025;45:3331024251353421.
    >> Share

  48. TASMA Z, Hay DL
    Decoding PACAP signaling: Splice variants, pathways and designer drugs.
    Cephalalgia. 2025;45:3331024251363560.
    >> Share

  49. SACCO S
    The "Migraines" epidemic: Exposing the challenges of artificial intelligence in scientific writing.
    Cephalalgia. 2025;45:3331024251365833.
    >> Share

  50. VALENCA MM
    Proposal of a migraine with associated myofascial pain phenotype: Bridging corpalgia, fibromyalgia and chronic migraine.
    Cephalalgia. 2025;45:3331024251360223.
    >> Share

  51. VAN VEELEN N, Pelzer N, van der Arend BWH, Waslam N, et al
    The psychometric properties of an e-headache diary in migraine.
    Cephalalgia. 2025;45:3331024251359222.
    >> Share

  52. CHRISTENSEN RH, Strassman AM, Ashina M, Ashina H, et al
    Opening of ATP-sensitive potassium channels activates meningeal nociceptors: Implications for the origin of migraine headache.
    Cephalalgia. 2025;45:3331024251359237.
    >> Share

  53. DOMINGUEZ-MORENO R, Karlsson WK, Al-Khazali HM, Christensen RH, et al
    Plasma adrenomedullin levels in migraine: A registry for migraine (REFORM) study.
    Cephalalgia. 2025;45:3331024251360234.
    >> Share

  54. CHRISTENSEN RH, Al-Khazali HM, Ashina M, Vashchenko N, et al
    Differences in cortical morphometry between persistent post-traumatic headache, migraine and healthy controls.
    Cephalalgia. 2025;45:3331024251362830.
    >> Share

  55. JOHNSON MP, Krikke-Workel J, Patel CN, Morin SM, et al
    Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine.
    Cephalalgia. 2025;45:3331024251368757.
    >> Share

  56. FERREIRA KDS, Velly AM
    Acute confusional migraine: Proposal for inclusion in the International Classification of Headache Disorders - 4th edition (ICHD-4).
    Cephalalgia. 2025;45:3331024251370305.
    >> Share

  57. ASHINA S, Ashina M, Holle-Lee D, Tassorelli C, et al
    Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.
    Cephalalgia. 2025;45:3331024251365206.
    >> Share

  58. EDVINSSON L
    Is PACAP the next big thing in migraine therapy?
    Cephalalgia. 2025;45:3331024251368748.
    >> Share

  59. PELES I, Sharvit S, Steen YM, Gordon M, et al
    Invisible burdens: Gender-specific associations between migraine and work-family conflict: Insights from the SMILE project - a cohort study.
    Cephalalgia. 2025;45:3331024251352533.
    >> Share

  60. RUSSO A, Silvestro M, Finkelstein I, Seabi D, et al
    Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence.
    Cephalalgia. 2025;45:3331024251370608.
    >> Share

  61. THURAIAIYAH J, Christensen RH, Al-Khazali HM, Wiggers A, et al
    Overlap between perceived triggers, premonitory symptoms and symptom persistence across migraine phases: A REFORM study.
    Cephalalgia. 2025;45:3331024251364234.
    >> Share

  62. ZHAI Q, Li H, Chen Q, Zhang N, et al
    Microglial TRPV2-mediated neuroinflammation promotes central sensitization through microglial polarization in a vestibular migraine mouse model.
    Cephalalgia. 2025;45:3331024251364753.
    >> Share

    July 2025
  63. CHAN NJ, Chen YY, Hsu CC, Lin YS, et al
    Sensitizing effect of antimigraine drug sumatriptan on capsaicin-sensitive lung vagal neurons via 5-HT(1B/1D) receptors and PKA: Relevance to adverse chest effects.
    Cephalalgia. 2025;45:3331024251355949.
    >> Share

  64. ROMOZZI M, Scipioni L, Di Tella S, Silveri MC, et al
    Genetic characterization of the endocannabinoid system and psychiatric features in patients with migraine and medication overuse headache.
    Cephalalgia. 2025;45:3331024251314460.
    >> Share

  65. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
    Grey-matter network topology in migraine with aura.
    Cephalalgia. 2025;45:3331024251353146.
    >> Share

  66. NIELSEN BS, Wang H, Ramdal Techlo T, Kogelman L, et al
    Genome sequencing reveals the Adgrl3 (ADGRL3) gene as a possible cause of cephalic hypersensitivity in the STA rat and migraine in humans.
    Cephalalgia. 2025;45:3331024251352844.
    >> Share

  67. HU YY, Mei HR, Sankar S, Pirwani A, et al
    Post-stress modulation of the HPA and melanocortin systems alleviates migraine-like behaviors in mice.
    Cephalalgia. 2025;45:3331024251352856.
    >> Share

  68. AILANI J, Pavlovic J, Pixton GC, Fullerton T, et al
    Rimegepant safety and patient-reported outcomes among triptan-naive, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study.
    Cephalalgia. 2025;45:3331024251343309.
    >> Share

  69. ZHUANG ZA, Al-Karagholi MA, Ashina H, Do TP, et al
    Effect of sumatriptan on ATP-sensitive potassium channel opening in migraine: A randomised controlled trial.
    Cephalalgia. 2025;45:3331024251341464.
    >> Share

  70. ANDREOU AP, Iannone LF
    The ongoing pursuit of migraine triggering mechanisms.
    Cephalalgia. 2025;45:3331024251342583.
    >> Share

  71. VILLAR-MARTINEZ MD, Goadsby PJ
    Cranial autonomic symptoms as a protective mechanism in patients with chronic migraine: A cross-sectional study.
    Cephalalgia. 2025;45:3331024251359564.
    >> Share

  72. BOTTIROLI S, Cangelosi M, Allena M, Icco R, et al
    Childhood traumas delineate a distinct psychological and clinical profile in adults with migraine: The hidden burden.
    Cephalalgia. 2025;45:3331024251358503.
    >> Share

  73. BOCZARSKA-JEDYNAK M, Blumenfeld AM
    When should the effectiveness of a botulinum toxin A for chronic migraine be assessed in the face of newest International Headache Society recommendations?
    Cephalalgia. 2025;45:3331024251363268.
    >> Share

  74. ALSAADI T, Suliman R, Yang J, Agarwal E, et al
    A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine.
    Cephalalgia. 2025;45:3331024251355947.
    >> Share

  75. PETRUSIC I
    Digital phenotyping for migraine: A game-changer for research and management.
    Cephalalgia. 2025;45:3331024251363568.
    >> Share

  76. SUZUKI Y, Kiyosawa M
    Characteristics of visual snow syndrome in Japan and its association with migraine.
    Cephalalgia. 2025;45:3331024251360337.
    >> Share

  77. TEPPER SJ, Jenkins A, Henriksen C, Dai F, et al
    A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data.
    Cephalalgia. 2025;45:3331024251352849.
    >> Share

    June 2025
  78. CHAUDHRY BA, Younis S, Messina R, Garcia-Azorin D, et al
    Cortical thickness studies in migraine: Current evidence and future directions.
    Cephalalgia. 2025;45:3331024251341204.
    >> Share

  79. SILVESTRO M, Orologio I, Sozio P, Dortucci V, et al
    No additional benefit with detoxification strategies: A real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies.
    Cephalalgia. 2025;45:3331024251329808.
    >> Share

  80. JAIMES A, Rodriguez-Vico J, Pajares O, Eguilior Caffarena I, et al
    Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study.
    Cephalalgia. 2025;45:3331024251346925.
    >> Share

  81. ASHINA S, Kim G, Muenzel EJ, Buse DC, et al
    Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study.
    Cephalalgia. 2025;45:3331024251341243.
    >> Share

  82. WENNERSTEN T, Lindh JD, Nilsson Remahl AIM, Andersson ML, et al
    Higher socioeconomic status is associated with dispensation of monoclonal antibodies against calcitonin gene-related peptide in migraine: A nested case-control study.
    Cephalalgia. 2025;45:3331024251348648.
    >> Share

  83. LING YH, Pan LH, Chen SP, Chen WT, et al
    Comorbidity with fibromyalgia predicted poorer outcomes in patients with chronic migraine on flunarizine: Prospective proof-of-concept study.
    Cephalalgia. 2025;45:3331024251353412.
    >> Share

    May 2025
  84. WONG HT, Khan R, Buture A, Khalil M, et al
    OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull.
    Cephalalgia. 2025;45:3331024251327387.
    >> Share

  85. EMMENEGGER MJ, Gantenbein AR
    Philosophical aspects of migraine: Headache treatment is a human-to-human service.
    Cephalalgia. 2025;45:3331024251343225.
    >> Share

  86. SORRENTINO A, Di Lorenzo C
    Comment on: Setting higher standards for migraine prevention: A position statement of the International Headache Society.
    Cephalalgia. 2025;45:3331024251343217.
    >> Share

  87. GOZALOV E, Karlsson WK, Christensen RH, Al-Khazali HM, et al
    Serum GFAP and NfL levels in migraine: A registry for migraine (REFORM) study.
    Cephalalgia. 2025;45:3331024251338178.
    >> Share

  88. PORRECA F, Navratilova E, Dodick DW
    Advancing understanding of migraine pathophysiology and therapy by consideration of patient sex.
    Cephalalgia. 2025;45:3331024251339466.
    >> Share

  89. MORENO-AJONA D, Gosalia H, Hoffmann J, Goadsby PJ, et al
    Amylin and the amylin receptors in migraine: Is there another pathway to target?
    Cephalalgia. 2025;45:3331024251340066.
    >> Share

  90. RUSSO A, Reuter U
    Raising the bar in migraine prevention: Toward freedom and optimal control.
    Cephalalgia. 2025;45:3331024251331198.
    >> Share

  91. ORNELLO R, D'Atri A, De Icco R, De Santis F, et al
    Effectiveness of transcranial direct current stimulation and monoclonal antibodies acting on the CGRP as a combined treatment for migraine (TACTIC): Results of a randomized controlled trial.
    Cephalalgia. 2025;45:3331024251325567.
    >> Share

  92. GOLLION C, Ashina H, Hackert Christensen R, Al-Khazali HM, et al
    Intact white matter in adults with migraine: A REFORM MRI study.
    Cephalalgia. 2025;45:3331024251339423.
    >> Share

    April 2025
  93. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
    Reply to "What is the evolutionary disadvantage of migraine?".
    Cephalalgia. 2025;45:3331024251327377.
    >> Share

  94. LISICKI M, Schoenen J
    What is the evolutionary disadvantage of migraine?
    Cephalalgia. 2025;45:3331024251327361.
    >> Share

  95. MAS-DE-LES-VALLS R, Gomez-Dabo L, Caronna E, Gallardo VJ, et al
    Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days.
    Cephalalgia. 2025;45:3331024251332519.
    >> Share

  96. VALENCA MM, Szewczyk AK
    Stroke-like migraine attacks after radiation therapy (SMART) syndrome: A call for standardized diagnostic criteria.
    Cephalalgia. 2025;45:3331024251334355.
    >> Share

  97. ROBBLEE J
    Rethinking status migrainosus: Escalation shouldn't wait for 72 hours.
    Cephalalgia. 2025;45:3331024251334137.
    >> Share

  98. VERNIERI F, Iannone LF, Lo Castro F, Sebastianelli G, et al
    Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study).
    Cephalalgia. 2025;45:3331024251335927.
    >> Share

  99. HAGHDOOST F
    Internet and social media's role in migraine education: Headache or not headache?
    Cephalalgia. 2025;45:3331024251336152.
    >> Share

  100. AL-KHAZALI HM, Christensen RH, Ashina H
    Clinical comparisons between post-traumatic headache and migraine: A cross-sectional study.
    Cephalalgia. 2025;45:3331024251331605.
    >> Share

  101. GONZALEZ-MARTINEZ A, Wei DY, Karsan N, Nagaraj K, et al
    Evaluation of premonitory spontaneous and nitroglycerin triggered symptoms among patients with cluster headache and migraine.
    Cephalalgia. 2025;45:3331024251331554.
    >> Share

  102. MESSINA R, Chong CD
    Migraine and the white matter microstructure controversy: Time for a methodological reset?
    Cephalalgia. 2025;45:3331024251339431.
    >> Share

  103. SEBASTIANELLI G
    The 'theory of everything' for migraine pathophysiology will never exist: Insights from glial cells.
    Cephalalgia. 2025;45:3331024251338171.
    >> Share

  104. ORNELLO R, Caponnetto V, Ahmed F, Al-Khazali HM, et al
    Evidence-based guidelines for the pharmacological treatment of migraine, summary version.
    Cephalalgia. 2025;45:3331024251321500.
    >> Share

  105. ORNELLO R, Caponnetto V, Ahmed F, Al-Khazali HM, et al
    Evidence-based guidelines for the pharmacological treatment of migraine.
    Cephalalgia. 2025;45:3331024241305381.
    >> Share

    March 2025
  106. OMLAND PM, Hansen JO, Neverdahl JP, Mykland MS, et al
    Migraine and insufficient sleep: The effect of sleep restriction on nociceptive evoked potentials in migraine.
    Cephalalgia. 2025;45:3331024251329400.
    >> Share

  107. PULEDDA F, Tassorelli C
    Reply to "Reassessing partial efficacy or not responding to acute migraine treatment".
    Cephalalgia. 2025;45:3331024251325543.
    >> Share

  108. POZO-ROSICH P, van Veelen N, Caronna E, Vaghi G, et al
    Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache.
    Cephalalgia. 2025;45:3331024251318016.
    >> Share

  109. YANG L, Jin T, Wang H
    Reassessing partial efficacy or not responding to acute migraine treatment.
    Cephalalgia. 2025;45:3331024251325526.
    >> Share

  110. BAI Y, Chu MK, Kang JJ, Chae J, et al
    No change in interictal plasma and salivary CGRP levels in individuals with vestibular migraine corresponding to episodic migraine.
    Cephalalgia. 2025;45:3331024251322418.
    >> Share

    February 2025
  111. GUZMAN G, Kopruszinski CM, Barber KR, Lillo Vizin RC, et al
    Chronification of migraine sensitizes to CGRP in male and female mice.
    Cephalalgia. 2025;45:3331024251317446.
    >> Share

  112. CHEEMA S, Lagrata S, Rantell KR, Ahmed M, et al
    OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine.
    Cephalalgia. 2025;45:3331024251317448.
    >> Share

  113. GANTENBEIN AR
    Depression screening in migraine - A double-edged sword.
    Cephalalgia. 2025;45:3331024251317606.
    >> Share

  114. GOADSBY PJ, Jurgens TP, Brand-Schieber E, Nagy K, et al
    Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.
    Cephalalgia. 2025;45:3331024251320610.
    >> Share

  115. SACCO S, Ashina M, Diener HC, Haghdoost F, et al
    Setting higher standards for migraine prevention: A position statement of the International Headache Society.
    Cephalalgia. 2025;45:3331024251320608.
    >> Share

  116. ASHEER J, Ali F, Hilker R, Videbech P, et al
    Methodological challenges in using screening tools for depression in migraine: A systematic review.
    Cephalalgia. 2025;45:3331024251317635.
    >> Share

  117. SZABO E, Bolo NR, Borsook D, Burstein R, et al
    Peripherally acting anti-CGRP monoclonal antibodies attenuate cortical resting-state connectivity in migraine patients.
    Cephalalgia. 2025;45:3331024241313377.
    >> Share

  118. LIAO YH, Tzeng YS, Chen SP, Ling YH, et al
    Association between headache frequency and risk for fibromyalgia in patients with migraine.
    Cephalalgia. 2025;45:3331024251317486.
    >> Share

  119. ZORRILLA E, Krivoshein G, Kuburas A, Schenke M, et al
    Combined effects of cannabidiol and Delta9-tetrahydrocannabinol alleviate migraine-like symptoms in mice.
    Cephalalgia. 2025;45:3331024251314487.
    >> Share

    January 2025
  120. STAEHR C, Nyegaard M, Bach FW, Rohde PD, et al
    Exploring the association between familial hemiplegic migraine genes (CACNA1A, ATP1A2 and SCN1A) with migraine and epilepsy: A UK Biobank exome-wide association study.
    Cephalalgia. 2025;45:3331024241306103.
    >> Share

  121. MOHAMMAD S, Bussu G, Rukh G, Schioth HB, et al
    Migraine and its major subtypes - with and without aura are associated with polygenic scores for autism.
    Cephalalgia. 2025;45:3331024241312666.
    >> Share

  122. LEE GJ, Hode V, Georgieva T, Rau J, et al
    Prolactin-induced sensitization of trigeminal nociceptors promotes migraine co-morbidity in endometriosis.
    Cephalalgia. 2025;45:3331024241313378.
    >> Share

  123. VAN DER AREND BWH, van Welie FC, Olsen MH, Versijpt J, et al
    Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications.
    Cephalalgia. 2025;45:3331024241297673.
    >> Share

    December 2024
  124. GENDOLLA A, Brown JD, Mercadante AR, Drakeley S, et al
    The incremental burden and healthcare resource utilization among people with migraine in Europe: Insights from the 2020 European National Health and Wellness Survey.
    Cephalalgia. 2024;44:3331024241276415.
    >> Share


  125. Abstracts of the 20(th) Biennial Migraine Trust International Symposium, London UK, 5th to 8th September 2024.
    Cephalalgia. 2024;44:3331024241280496.
    >> Share

  126. OLESEN J, Tfelt-Hansen P
    Methodology of drug trials in migraine: History and suggestions for the future.
    Cephalalgia. 2024;44:3331024241298642.
    >> Share

  127. ROMOZZI M, Lokhandwala A, Vollono C, Vigani G, et al
    An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine.
    Cephalalgia. 2024;44:3331024241262751.
    >> Share

  128. PETERLIN BL, Bond DS, Ailani J, Dodick DW, et al
    Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis.
    Cephalalgia. 2024;44:3331024241299753.
    >> Share

  129. GOTTSCHALK C, Gandhi P, Pozo-Rosich P, Christie S, et al
    Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials.
    Cephalalgia. 2024;44:3331024241300305.
    >> Share

    November 2024
  130. BURGALASSI A, Romozzi M, Vigani G, De Icco R, et al
    Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study.
    Cephalalgia. 2024;44:3331024241273968.
    >> Share

  131. SACCO S, De Santis F, Onofri A, Rosignoli C, et al
    A call for academic pragmatic clinical trials to address open questions in migraine prevention.
    Cephalalgia. 2024;44:3331024241291574.
    >> Share

  132. CLOET F, Gueyraud G, Lerebours F, Munio M, et al
    Stroke due to small-vessel disease and migraine: A case-control study of a young adult with ischemic stroke population.
    Cephalalgia. 2024;44:3331024241282015.
    >> Share

  133. AILANI J, Lalla A, Halker Singh RB, Holle-Lee D, et al
    Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies.
    Cephalalgia. 2024;44:3331024241299377.
    >> Share

  134. PULEDDA F, de Boer I, Messina R, Garcia-Azorin D, et al
    Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society.
    Cephalalgia. 2024;44:3331024241297688.
    >> Share

  135. YANG C, Wei C, Alam S, Chen X, et al
    The neurotrophic factor artemin and its receptor GFRalpha3 mediate migraine-like pain via the ion channel TRPM8.
    Cephalalgia. 2024;44:3331024241297679.
    >> Share

  136. DALLA VOLTA G, Russo A, Silvestro M, Ornello R, et al
    Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study.
    Cephalalgia. 2024;44:3331024241299453.
    >> Share

    October 2024
  137. SEBASTIANELLI G, Atalar AC, Cetta I, Farham F, et al
    Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis.
    Cephalalgia. 2024;44:3331024241287224.
    >> Share

  138. PELES I, Sharvit S, Zlotnik Y, Gordon M, et al
    Migraine and work - beyond absenteeism: Migraine severity and occupational burnout - A cohort study.
    Cephalalgia. 2024;44:3331024241289930.
    >> Share

  139. CAMMAROTA F, De Icco R, Vaghi G, Corrado M, et al
    High-frequency episodic migraine: Time for its recognition as a migraine subtype?
    Cephalalgia. 2024;44:3331024241291578.
    >> Share

  140. TRILLER P, Blessing VN, Overeem LH, Fitzek MP, et al
    Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study.
    Cephalalgia. 2024;44:3331024241288875.
    >> Share

    September 2024
  141. ACARSOY C, Ikram MK, Ikram MA, Vernooij MW, et al
    Migraine and brain structure in the elderly: The Rotterdam Study.
    Cephalalgia. 2024;44:3331024241266951.
    >> Share

  142. KOPRUSZINSKI CM, Lee G, Martin LK, Barber KR, et al
    A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache.
    Cephalalgia. 2024;44:3331024241281493.
    >> Share

  143. PULEDDA F, Sacco S, Diener HC, Ashina M, et al
    International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine.
    Cephalalgia. 2024;44:3331024241269735.
    >> Share

  144. IHARA K, Casillo F, Dahshan A, Genc H, et al
    Are we closer to achieving precision medicine for migraine treatment? A narrative review.
    Cephalalgia. 2024;44:3331024241281518.
    >> Share

  145. MELO-CARRILLO A, Strassman AM, Malcolm KJ, Adams AM, et al
    Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female rats.
    Cephalalgia. 2024;44:3331024241278919.
    >> Share

  146. WILCHA RJ, Goadsby PJ
    Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study.
    Cephalalgia. 2024;44:3331024241278911.
    >> Share

  147. CASILLO F, Di Renzo A, Sebastianelli G, Abagnale C, et al
    Lack of a direct link between macular cones function and photophobia in interictal migraine.
    Cephalalgia. 2024;44:3331024241276501.
    >> Share

  148. ASHINA M, Steiner TJ, Hansen JM, Hauberg DS, et al
    Cost of illness and labour market disaffiliation among patients with migraine discontinuing triptan treatment: A Danish nationwide register study from 1995 to 2021.
    Cephalalgia. 2024;44:3331024241269758.
    >> Share

  149. ERNSTSEN C, Obelitz-Ryom K, Kristensen DMB, Olesen J, et al
    Mechanisms of GTN-induced migraine: Role of NOS isoforms, sGC and peroxynitrite in a migraine relevant mouse model.
    Cephalalgia. 2024;44:3331024241277542.
    >> Share

  150. ELOSUA-BAYES I, Alpuente A, Melgarejo L, Caronna E, et al
    Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data.
    Cephalalgia. 2024;44:3331024241273966.
    >> Share

    August 2024
  151. DO TP
    Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications.
    Cephalalgia. 2024;44:3331024241268058.
    >> Share

  152. OMLAND PM
    Enhanced learning in migraine: False positive finding or discovery of a new migraine trait?
    Cephalalgia. 2024;44:3331024241268297.
    >> Share

  153. STUBBERUD A, Borkenhagen S, Oteiza F, Dueland AN, et al
    Patterns of migraine medication use in Norway: A nationwide registry-based observational study.
    Cephalalgia. 2024;44:3331024241268212.
    >> Share

  154. PULEDDA F, Sacco S, Diener HC, Ashina M, et al
    International Headache Society global practice recommendations for the acute pharmacological treatment of migraine.
    Cephalalgia. 2024;44:3331024241252666.
    >> Share

  155. KATSARAVA Z, Buse DC, Leroux E, Lanteri-Minet M, et al
    Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study.
    Cephalalgia. 2024;44:3331024241274343.
    >> Share

  156. SIMMONDS L, Jamtoy KA, Aschehoug I, Hara S, et al
    Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine.
    Cephalalgia. 2024;44:3331024241273967.
    >> Share

  157. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
    Effects of levcromakalim in patients with migraine aura without headache: An experimental study.
    Cephalalgia. 2024;44:3331024241274366.
    >> Share

  158. HU YY, Souza R, Muthuraman A, Knapp L, et al
    Glucocorticoid signaling mediates stress-induced migraine-like behaviors in a preclinical mouse model.
    Cephalalgia. 2024;44:3331024241277941.
    >> Share

  159. MULLIN K, Croop R, Mosher L, Fullerton T, et al
    Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
    Cephalalgia. 2024;44:3331024241259456.
    >> Share

  160. AL-KHAZALI HM, Al-Sayegh Z, Younis S, Christensen RH, et al
    Systematic review and meta-analysis of Neck Disability Index and Numeric Pain Rating Scale in patients with migraine and tension-type headache.
    Cephalalgia. 2024;44:3331024241274266.
    >> Share

  161. PERES MFP, Sacco S, Pozo-Rosich P, Tassorelli C, et al
    Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: A call to action.
    Cephalalgia. 2024;44:3331024241267309.
    >> Share

    July 2024
  162. RUSCHEWEYH R, Forderreuther S, Freilinger T, Gaul C, et al
    Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry.
    Cephalalgia. 2024 Jul 21:3331024241261077. doi: 10.1177/03331024241261077.
    >> Share

  163. DE VRIES T, Boucherie DM, Chan KY, Rubio-Beltran E, et al
    Sex differences in CGRP-induced vasodilation of human middle meningeal arteries but not human coronary arteries: implications for migraine.
    Cephalalgia. 2024;44:3331024241254088.
    >> Share

  164. TOT K, Braunitzer G, Harcsa-Pinter N, Kiss A, et al
    Enhanced audiovisual associative pair learning in migraine without aura in adult patients: An unexpected finding.
    Cephalalgia. 2024;44:3331024241258722.
    >> Share

    June 2024
  165. EXACOUSTOS C, Martire FG, Albanese M, Selntigia A, et al
    REPLY to Comment on Correlation between endometriosis and migraine features: Results from a prospective case-control study'': Correlation between endometriosis and migraine features is not based on a broad strokes results.
    Cephalalgia. 2024;44:3331024241254821.
    >> Share

  166. LIU L, Chen Q, Zhao L, Lyu T, et al
    Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial.
    Cephalalgia. 2024;44:3331024241261080.
    >> Share

  167. ISHII R, Ishizuchi K, Watanabe N, Fukazawa R, et al
    Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.
    Cephalalgia. 2024;44:3331024241258695.
    >> Share

  168. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
    Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.
    Cephalalgia. 2024;44:3331024241258734.
    >> Share

  169. RAFFAELLI B, Do TP, Ashina H, Snellman J, et al
    Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation.
    Cephalalgia. 2024;44:3331024241259489.
    >> Share

  170. LI H, Xu X, Xu R, Fan PX, et al
    Latent class analysis of migraine associated vestibular-auditory symptoms.
    Cephalalgia. 2024;44:3331024241262488.
    >> Share

  171. BRAILLON A
    Registry-based safety studies of migraine drugs in pregnancy: Acknowledging our failures.
    Cephalalgia. 2024;44:3331024241262486.
    >> Share


  172. Corrigendum to "Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials".
    Cephalalgia. 2024;44:3331024241255216.
    >> Share


  173. Corrigendum to: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Cephalalgia. 2024;44:3331024241254952.
    >> Share

    May 2024
  174. RASMUSSEN AV, Jensen RH, Gantenbein A, Sumelahti ML, et al
    Consensus recommendations on the role of nurses in headache care: A European e-Delphi study.
    Cephalalgia. 2024;44:3331024241252161.
    >> Share

  175. KOKOTI L, Al-Karagholi MA, Zhuang ZA, Amirguliyev S, et al
    Non-vascular ATP-sensitive potassium channel activation does not trigger migraine attacks: A randomized clinical trial.
    Cephalalgia. 2024;44:3331024241248211.
    >> Share

  176. AKGOR U, Ince O
    Comment on ''Correlation between endometriosis and migraine features: Results from a prospective case-control study''.
    Cephalalgia. 2024;44:3331024241254824.
    >> Share

  177. GIRI S, Tronvik E, Dalen H, Ellekjaer H, et al
    Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trondelag Health Study.
    Cephalalgia. 2024;44:3331024241254517.
    >> Share

  178. AL-HASSANY L, Boucherie DM, Couturier EGM, MaassenVanDenBrink A, et al
    Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?
    Cephalalgia. 2024;44:3331024241248837.
    >> Share

    April 2024
  179. RATTANAWONG W, Rapoport A, Srikiatkhachorn A
    Medication "underuse" headache.
    Cephalalgia. 2024;44:3331024241245658.
    >> Share

  180. MITTER VR, Lupattelli A, Bjork MH, Nordeng HME, et al
    Identification and characterization of migraine in pregnancy: A Norwegian registry-based cohort study.
    Cephalalgia. 2024;44:3331024241248846.
    >> Share

  181. GARCIA-AZORIN D, Martinez-Badillo C, Camina Muniz J, Gago-Veiga AB, et al
    CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.
    Cephalalgia. 2024;44:3331024241248833.
    >> Share

  182. WHITAKER DJ, Dumkrieger GM, Hentz JG, Dodick DW, et al
    Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine.
    Cephalalgia. 2024;44:3331024241249747.
    >> Share

  183. CROOP R, Berman G, Kudrow D, Mullin K, et al
    A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
    Cephalalgia. 2024;44:3331024241232944.
    >> Share

  184. OLFAT M, Hosseinpour S, Masoumi S, Gogia Rastogi R, et al
    A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: a randomized double-blind clinical trial.
    Cephalalgia. 2024;44:3331024241230963.
    >> Share

    March 2024
  185. PASCUAL-MATO M, Garate G, de Prado-Tejerina C, Garcia MJ, et al
    Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study.
    Cephalalgia. 2024;44:3331024241233979.
    >> Share

  186. SELNTIGIA A, Exacoustos C, Ortoleva C, Russo C, et al
    Correlation between endometriosis and migraine features: Results from a prospective case-control study.
    Cephalalgia. 2024;44:3331024241235210.
    >> Share

  187. PORRECA F, Navratilova E, Hirman J, van den Brink AM, et al
    Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Cephalalgia. 2024;44:3331024241238153.
    >> Share

  188. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
    Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura.
    Cephalalgia. 2024;44:3331024241237247.
    >> Share

  189. LAMAS PEREZ R, Millan-Vazquez M, Gonzalez-Oria C
    Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
    Cephalalgia. 2024;44:3331024231226181.
    >> Share

  190. SACCO S, Porreca F
    Breaking barriers in migraine care: Advancing gender medicine to bridge the gap for men.
    Cephalalgia. 2024;44:3331024241238157.
    >> Share

  191. DIENER HC, May A
    New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication.
    Cephalalgia. 2024;44:3331024241228605.
    >> Share

  192. ASHINA H, Diener HC, Tassorelli C, Scher AI, et al
    Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury.
    Cephalalgia. 2024;44:3331024241234068.
    >> Share

    February 2024
  193. TORRES-FERRUS M, Gallardo VJ, Alpuente A, Caronna E, et al
    Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
    Cephalalgia. 2024;44:3331024231222923.
    >> Share

  194. THURAIAIYAH J, Ashina H, Christensen RH, Al-Khazali HM, et al
    Premonitory symptoms in migraine: A REFORM Study.
    Cephalalgia. 2024;44:3331024231223979.
    >> Share

  195. PHILLIPS K, Clerkin-Oliver C, Nirantharakumar K, Crowe FL, et al
    How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis.
    Cephalalgia. 2024;44:3331024241229410.
    >> Share

  196. VIANA M, Hougaard A, Tronvik E, Winnberg IG, et al
    Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura.
    Cephalalgia. 2024;44:3331024241234809.
    >> Share

  197. IKUMI N, Marti-Marca A, Torre-Sune A, Cerda-Company X, et al
    Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study.
    Cephalalgia. 2024;44:3331024241230279.
    >> Share

  198. TASSORELLI C, Onishchenko K, Halker Singh RB, Duan M, et al
    Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
    Cephalalgia. 2024;44:3331024241235156.
    >> Share

  199. SHEWALE AR, Brandenburg JA, Burslem K, Lipton RB, et al
    Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine.
    Cephalalgia. 2024;44:3331024241235139.
    >> Share

    January 2024
  200. COPPOLA G, Renzo AD, Parisi V, Serrao M, et al
    Comment on "Lack of reproducibility of resting-state functional MRI findings in migraine with aura".
    Cephalalgia. 2024;44:3331024231225186.
    >> Share

  201. PICO MJ, Badri M, Michalak N, Siefferman JW, et al
    Systemic allergic reaction to galcanezumab (emgality): a case report.
    Cephalalgia. 2024;44:3331024231222914.
    >> Share

  202. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
    Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses.
    Cephalalgia. 2024;44:3331024231222637.
    >> Share

  203. BUGGE NS, Grotta Vetvik K, Alstadhaug KB, Braaten T, et al
    Cumulative exposure to estrogen may increase the risk of migraine in women.
    Cephalalgia. 2024;44:3331024231225972.
    >> Share

  204. FLORESCU AM, Lannov LV, Younis S, Cullum CK, et al
    No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
    Cephalalgia. 2024;44:3331024231222915.
    >> Share

  205. RAHMAN SM, Luebke AE
    Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models.
    Cephalalgia. 2024;44:3331024231223971.
    >> Share

  206. RAFFAELLI B, Do TP, Chaudhry BA, Amin FM, et al
    Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial.
    Cephalalgia. 2024;44:3331024231222916.
    >> Share

  207. MONTE G, Papetti L, Ursitti F, Sforza G, et al
    Childhood primary stabbing headache: A double center study.
    Cephalalgia. 2024;44:3331024231225974.
    >> Share

  208. KRISTOFFERSEN ES, Pallesen S, Waage S, Bjorvatn B, et al
    The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study.
    Cephalalgia. 2024;44:3331024231226323.
    >> Share

    December 2023
  209. BASEDAU H, Ornello R, Matteis E, Davaasuren B, et al
    Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?
    Cephalalgia. 2023;43:3331024231218392.
    >> Share

  210. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
    The evolutionary meaning of migraine.
    Cephalalgia. 2023;43:3331024231209303.
    >> Share

  211. TEZUKA T, Shibata M, Hanaoka H, Izawa Y, et al
    Systemic lupus erythematosus mimicking retinal migraine: a case report.
    Cephalalgia. 2023;43:3331024231219477.
    >> Share

  212. DOBOS D, Kokonyei G, Gyebnar G, Szabo E, et al
    Microstructural differences in migraine: A diffusion-tensor imaging study.
    Cephalalgia. 2023;43:3331024231216456.
    >> Share

  213. AL-KARAGHOLI MA
    Targeting CGRP pathways and aura: A peripheral site with a central effect.
    Cephalalgia. 2023;43:3331024231212895.
    >> Share

  214. CHRISTOPHERSEN P, Dyhring T
    The shortcoming of using glibenclamide in exploratory clinical headache provocation studies.
    Cephalalgia. 2023;43:3331024231219475.
    >> Share

    November 2023
  215. VAN DER AREND B, Terwindt GM
    Response to Letter to the Editor, Comment on "Effect of COVID vaccinations on monthly migraine days".
    Cephalalgia. 2023;43:3331024231208123.
    >> Share

  216. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on "Effect of COVID vaccination on monthly migraine days".
    Cephalalgia. 2023;43:3331024231208121.
    >> Share

  217. AL-KHAZALI HM, Christensen RH, Dodick DW, Chaudhry BA, et al
    Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache.
    Cephalalgia. 2023;43:3331024231210930.
    >> Share

  218. NAVARRO-PEREZ MP, Santos-Lasaosa S, Olesen J
    Evaluation of the ICHD-3 diagnostic criteria for cardiac cephalalgia and new proposal.
    Cephalalgia. 2023;43:3331024231202243.
    >> Share

  219. HOUGAARD A, Gaist D, Garde E, Iversen P, et al
    Lack of reproducibility of resting-state functional MRI findings in migraine with aura.
    Cephalalgia. 2023;43:3331024231212574.
    >> Share

  220. BAHRA A
    Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment.
    Cephalalgia. 2023;43:3331024231214239.
    >> Share

  221. GARCIA-AZORIN D, Santana-Lopez L, Lozano-Alonso JE, Ordax-Diez A, et al
    InfluenCEF study: Clinical phenotype and duration of headache attributed to influenza infection.
    Cephalalgia. 2023;43:3331024231212900.
    >> Share

  222. ASHINA M, Mitsikostas DD, Amin FM, Kokturk P, et al
    Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
    Cephalalgia. 2023;43:3331024231214987.
    >> Share

    October 2023
  223. SEBASTIANELLI G, Casillo F, Abagnale C, Renzo AD, et al
    Central sensitization mechanisms in chronic migraine with medication overuse headache: a study of thalamocortical activation and lateral cortical inhibition.
    Cephalalgia. 2023;43:3331024231202240.
    >> Share

  224. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
    An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study.
    Cephalalgia. 2023;43:3331024231206375.
    >> Share

  225. DEV P, Favas TT, Jaiswal R, Cyriac M, et al
    The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial.
    Cephalalgia. 2023;43:3331024231182684.
    >> Share

  226. CHUANG CH, Li JY, King JT, Chen WT, et al
    Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study.
    Cephalalgia. 2023;43:3331024231206781.
    >> Share

  227. CHRISTENSEN RH, Eigenbrodt AK, Ashina H, Steiner TJ, et al
    What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies.
    Cephalalgia. 2023;43:3331024231206376.
    >> Share

  228. KUAN AS, Chen SP, Wang YF, Wang SJ, et al
    Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine.
    Cephalalgia. 2023;43:3331024231208110.
    >> Share

  229. ZLOOF Y, Tsur AM, Simchoni M, Derazne E, et al
    Body mass index and migraine in adolescence: A nationwide study.
    Cephalalgia. 2023;43:3331024231209309.
    >> Share

  230. ALEKSOVSKA K, Hershey AD, Deen M, Icco R, et al
    Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society.
    Cephalalgia. 2023;43:3331024231206162.
    >> Share

  231. BELIN AC, Barloese MC
    The genetics and chronobiology of cluster headache.
    Cephalalgia. 2023;43:3331024231208126.
    >> Share

    September 2023
  232. VAN DER AREND BWH, Bloemhof MM, van der Schoor AG, van Zwet EW, et al
    Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study.
    Cephalalgia. 2023;43:3331024231198792.
    >> Share

    August 2023
  233. ALPUENTE A, Torre-Sune A, Caronna E, Gine-Cipres E, et al
    Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
    Cephalalgia. 2023;43:3331024231177636.
    >> Share

  234. LA ROCCA M, Laporta A, Clemente L, Ammendola E, et al
    Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients.
    Cephalalgia. 2023;43:3331024231189751.
    >> Share

  235. ADAM I, Elmugabil A, AlHabardi N
    History of maternal migraine and its association with preeclampsia: A case-control study in a low-resource setting in Sudan, Africa.
    Cephalalgia. 2023;43:3000605231193823.
    >> Share

  236. PULEDDA F, Vigano A, Sebastianelli G, Parisi V, et al
    Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: A narrative review.
    Cephalalgia. 2023;43:3331024231195780.
    >> Share

  237. LIPTON RB, Halker Singh RB, Mechtler L, McVige J, et al
    Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Cephalalgia. 2023;51:3331024231190296.
    >> Share

    July 2023
  238. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
    Symptoms associated with headache in youth.
    Cephalalgia. 2023;43:3331024231187162.
    >> Share

    June 2023
  239. VERHAGEN IE, van der Arend BW, van Casteren DS, Thiermann NJ, et al
    Migraine with and without aura in relation to the menstrual cycle and other hormonal milestones: A prospective cohort study.
    Cephalalgia. 2023;43:3331024231164322.
    >> Share

  240. PELZER N, de Boer I, van den Maagdenberg AMJM, Terwindt GM, et al
    Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives.
    Cephalalgia. 2023;43:3331024231180564.
    >> Share

  241. KLAN T, Gaul C, Liesering-Latta E, Witthoft M, et al
    Behavioral treatment for migraine prophylaxis in adults: Moderator analysis of a randomized controlled trial.
    Cephalalgia. 2023;43:3331024231178237.
    >> Share

  242. BERTZ R, Bhardwaj R, Morris BA, Ashbrenner E, et al
    A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
    Cephalalgia. 2023;43:3331024231179131.
    >> Share

  243. BUTURE A, Tomkins EM, Shukralla A, Troy E, et al
    Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the
    Cephalalgia. 2023;43:3331024231182126.
    >> Share

  244. ADAMS AM, Buse DC, Leroux E, Lanteri-Minet M, et al
    Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care.
    Cephalalgia. 2023;43:3331024231180611.
    >> Share

  245. CARCEL C, Haghdoost F, Shen J, Nanda P, et al
    The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231183166.
    >> Share

  246. THOMSEN AV, Puonti O, Gaist D, Kyvik KO, et al
    Investigations of the subarachnoid space as a potential link between aura and headache in migraine: A case-control MRI study.
    Cephalalgia. 2023;43:3331024231170541.
    >> Share

  247. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
    The prevalence and burden of medication overuse headache in Greece.
    Cephalalgia. 2023;43:3331024231184909.
    >> Share

    May 2023
  248. VAN DER AREND BWH, Verhagen IE, van Leeuwen M, van der Arend MQTP, et al
    Defining migraine days, based on longitudinal E-diary data.
    Cephalalgia. 2023;43:3331024231166625.
    >> Share

  249. CHEEMA S, Mehta D, Ray JC, Hutton EJ, et al
    New daily persistent headache: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231168089.
    >> Share

  250. STUBBERUD A, Ingvaldsen SH, Brenner E, Winnberg I, et al
    Forecasting migraine with machine learning based on mobile phone diary and wearable data.
    Cephalalgia. 2023;43:3331024231169244.
    >> Share

  251. ASHINA M, Lanteri-Minet M, Ettrup A, Christoffersen CL, et al
    Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
    Cephalalgia. 2023;43:3331024231170807.
    >> Share

  252. VAN WELIE RF, van Welie FC, de Vries Lentsch S, Dahan A, et al
    Characterizing opioid use in a Dutch cohort with migraine.
    Cephalalgia. 2023;43:3331024231174160.
    >> Share

  253. HSIAO FJ, Chen WT, Wang YF, Chen SP, et al
    Identification of patients with chronic migraine by using sensory-evoked oscillations from the electroencephalogram classifier.
    Cephalalgia. 2023;43:3331024231176074.
    >> Share

  254. GULDIKEN YC, Petropoulos IN, Malik A, Malik RA, et al
    Corneal confocal microscopy identifies corneal nerve fiber loss in patients with migraine.
    Cephalalgia. 2023;43:3331024231170810.
    >> Share

  255. RUSCHEWEYH R, Dresler T, Forderreuther S, Gaul C, et al
    What do patients' efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry.
    Cephalalgia. 2023;43:3331024231174855.
    >> Share

  256. STEINER TJ
    Classification of migraine and tension-type headache: A response to the proposals of Olesen.
    Cephalalgia. 2023;43:3331024231169240.
    >> Share

  257. SUZUKI K, Suzuki S, Shiina T, Tatsumoto M, et al
    Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Cephalalgia. 2023;43:3331024231177649.
    >> Share

  258. PARK CG, Na HY, Park DE, Kim HY, et al
    Altered interictal serum histamine and immunoglobulin E but unchanged tryptase levels in individuals with episodic and chronic migraine.
    Cephalalgia. 2023;43:3331024231178218.
    >> Share

  259. ABU-ARAFEH I, Hershey AD, Diener HC, Tassorelli C, et al
    Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition - An experience-based update.
    Cephalalgia. 2023;43:3331024231178239.
    >> Share

    April 2023
  260. GIRI S, Tronvik E, Linde M, Pedersen SA, et al
    Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231156922.
    >> Share

  261. OLESEN J, Jensen RH
    The Global Campaign Against Headache and its future relation to IHS and WHO.
    Cephalalgia. 2023;43:3331024231159625.
    >> Share

  262. HAGHDOOST F, Puledda F, Garcia-Azorin D, Huessler EM, et al
    Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Cephalalgia. 2023;43:3331024231159366.
    >> Share

  263. NIDDAM DM, Wu SW, Lai KL, Yang YY, et al
    An altered reward system characterizes chronic migraine with medication overuse headache.
    Cephalalgia. 2023;43:3331024231158088.
    >> Share

  264. ASAWAVICHIENJINDA T, Sathitratanacheewin S, Chokesuwattanaskul R
    "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials.
    Cephalalgia. 2023;43:3331024231161261.
    >> Share

  265. IANNONE LF, Burgalassi A, Vigani G, Tabasso G, et al
    Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
    Cephalalgia. 2023;43:3331024231160519.
    >> Share

  266. FAVONI V, Mascarella D, Giannini G, Bauleo S, et al
    Prevalence, natural history and dynamic nature of chronic headache and medication overuse headache in Italy: The SPARTACUS study.
    Cephalalgia. 2023;43:3331024231157677.
    >> Share

  267. ASHINA M, Roos C, Li LQ, Komori M, et al
    Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
    Cephalalgia. 2023;43:3331024231161745.
    >> Share

  268. ZHANG L, Zhou Y, Wang Y, Yang L, et al
    Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model.
    Cephalalgia. 2023;43:3331024231163131.
    >> Share

  269. RUSSO CV, Sacca F, Braca S, Sansone M, et al
    Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study.
    Cephalalgia. 2023;43:3331024231161809.
    >> Share

  270. OLESEN J
    Classification of migraine and tension-type headache.
    Cephalalgia. 2023;43:3331024221139238.
    >> Share

  271. CROWE HM, Wesselink AK, Hatch EE, Wise LA, et al
    Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study.
    Cephalalgia. 2023;43:3331024231161746.
    >> Share

  272. SAKAI F, Igarashi H, Yokoyama M, Begasse de Dhaem O, et al
    Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees.
    Cephalalgia. 2023;43:3331024231165682.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016